ストックスクリーナーアプリを入手
5.85
2.81%
0.16
アフターアワーズ：
6.00
0.15
+2.56%
前日終値:
$5.69
開ける：
$6
24時間の取引高:
49,487
Relative Volume:
0.44
時価総額：
$77.74M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-4.88%
1か月 パフォーマンス:
-26.04%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$5.69
$6.00
1週間の範囲:
$5.58
$6.36
52週間の値動き範囲:
$4.575
$19.40
Onkure Therapeutics Inc Stock (OKUR) Company Profile
名前
Onkure Therapeutics Inc
セクター
電話
(720) 307-2892
住所
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
OKUR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
5.85 | 77.74M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-05 | 開始されました | Leerink Partners | Outperform |
| 2024-10-10 | 開始されました | Oppenheimer | Outperform |
| 2023-12-15 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | ダウングレード | Jefferies | Buy → Hold |
| 2023-12-15 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-12-14 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | 開始されました | William Blair | Outperform |
| 2023-08-28 | 開始されました | H.C. Wainwright | Buy |
| 2023-07-03 | 開始されました | BofA Securities | Buy |
| 2022-09-19 | 再開されました | H.C. Wainwright | Buy |
| 2022-01-27 | 開始されました | Robert W. Baird | Outperform |
| 2021-12-21 | 開始されました | H.C. Wainwright | Buy |
| 2021-11-22 | 開始されました | Ladenburg Thalmann | Buy |
| 2021-05-04 | 開始されました | Jefferies | Buy |
| 2021-05-04 | 開始されました | Piper Sandler | Overweight |
| 2021-05-04 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Onkure Therapeutics Inc (OKUR) 最新ニュース
Vanguard Group Inc's Strategic Acquisition of OnKure Therapeutics Shares - GuruFocus.com
After A Clear Safety Picture, OnKure Prepares For Pivotal PIKture-01 Data On OKI-219 - RTTNews
Jones Trading sets OnKure stock Buy rating, $32 target - MSN
Jones Trading sets OnKure stock Buy rating, $32 target By Investing.com - Investing.com South Africa
Jones Trading Initiates Coverage of OnKure Therapeutics (OKUR) with Buy Recommendation - MSN
OnKure Therapeutics (NASDAQ:OKUR) Trading Down 3.4% – Here’s Why - Defense World
Reneo Pharmaceuticals stock hits 52-week low at $5.66 By Investing.com - Investing.com Australia
Reneo Pharmaceuticals stock hits 52-week low at $5.66 - Investing.com India
Reneo Pharmaceuticals stock hits 52-week low at $7.64 By Investing.com - Investing.com Australia
Reneo Pharmaceuticals stock hits 52-week low at $7.64 - Investing.com India
OnKure Therapeutics (NASDAQ:OKUR) Trading 4% Higher – Time to Buy? - Defense World
Reneo Pharmaceuticals stock hits 52-week low at $7.91 By Investing.com - Investing.com Nigeria
Reneo Pharmaceuticals stock hits 52-week low at $7.91 - Investing.com India
OKUR Stock Hits 52-Week Low at $10.51 Amid Market Challenges - Investing.com Australia
OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 - Markets Insider
OnKure reports positive early trial data for cancer drug OKI-219 - Investing.com India
OnKure Therapeutics Advances Cancer Drug Trials - TipRanks
Form 424B3 OnKure Therapeutics, - StreetInsider.com
SEC Form 424B3 filed by OnKure Therapeutics Inc. - Quantisnow
OnKure Therapeutics announces safety, pharmacokinetic data on OKI-219 - TipRanks
OnKure's OKI-219 Cancer Drug Shows Promising Safety Data, 95% Tumor Marker Reduction in Clinical Trial - StockTitan
Brokers Offer Predictions for OKUR FY2024 Earnings - Defense World
Leerink Partners Initiates Coverage of OnKure Therapeutics (OKUR) with Outperform Recommendation - MSN
OnKure Therapeutics stock has strong potential with Outperform rating from Leerink - Investing.com
OnKure Therapeutics Reports Strategic Merger and Financial Updates - TipRanks
OnKure Announces New Date for Upcoming Investor Call - GlobeNewswire
Head to Head Survey: OnKure Therapeutics (OKUR) vs. Its Rivals - Defense World
OnKure Therapeutics Faces Post-Merger Hurdles: Integration Challenges and Talent Competition Threaten Growth - MSN
OnKure Therapeutics (OKUR) vs. The Competition Head-To-Head Analysis - Defense World
OnKure Therapeutics' (OKUR) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
OnKure Therapeutics announces accounting firm change - Investing.com India
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
OnKure to Present at the Stifel 2024 Healthcare Conference - GlobeNewswire
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium - GlobeNewswire
vTv Therapeutics Faces License Agreement Termination - Yahoo Finance
VTv, OnKure Terminate Cellular Drug Licensing Agreement - MarketWatch
vTv Therapeutics ends key license agreement with OnKure - Investing.com
vTv Therapeutics ends key license agreement with OnKure By Investing.com - Investing.com UK
OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond (OKUR) - Seeking Alpha
Q3 Earnings Forecast for OKUR Issued By HC Wainwright - MarketBeat
Onkure Therapeutics Inc (OKUR) 財務データ
Onkure Therapeutics Inc (OKUR) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Onkure Therapeutics Inc (OKUR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Leonard Braden Michael | 10% Owner |
Sep 24 '24 |
Buy |
1.41 |
29,600 |
41,866 |
3,388,649 |
| Leonard Braden Michael | 10% Owner |
Sep 17 '24 |
Buy |
1.36 |
55,300 |
75,108 |
3,358,243 |
| Leonard Braden Michael | 10% Owner |
Sep 18 '24 |
Buy |
1.40 |
806 |
1,128 |
3,359,049 |
| Leonard Braden Michael | 10% Owner |
Sep 16 '24 |
Buy |
1.37 |
172,747 |
236,871 |
3,302,943 |
| Leonard Braden Michael | 10% Owner |
Sep 13 '24 |
Buy |
1.31 |
150,000 |
196,950 |
3,130,196 |
| Leonard Braden Michael | 10% Owner |
Sep 12 '24 |
Buy |
1.40 |
36,176 |
50,523 |
2,980,196 |
| Leonard Braden Michael | 10% Owner |
Aug 13 '24 |
Buy |
1.39 |
171,339 |
238,590 |
2,843,533 |
| Leonard Braden Michael | 10% Owner |
Aug 14 '24 |
Buy |
1.41 |
100,487 |
142,008 |
2,944,020 |
| Leonard Braden Michael | 10% Owner |
May 14 '24 |
Buy |
1.54 |
414,281 |
639,578 |
2,672,194 |
1.09%
大文字化:
|
ボリューム (24 時間):